MA30287B1 - Procedes de traitement de maladies inflammatoires et auto-immunes avec du natalizumab - Google Patents
Procedes de traitement de maladies inflammatoires et auto-immunes avec du natalizumabInfo
- Publication number
- MA30287B1 MA30287B1 MA31249A MA31249A MA30287B1 MA 30287 B1 MA30287 B1 MA 30287B1 MA 31249 A MA31249 A MA 31249A MA 31249 A MA31249 A MA 31249A MA 30287 B1 MA30287 B1 MA 30287B1
- Authority
- MA
- Morocco
- Prior art keywords
- natalizumab
- igg4
- concentrations
- autoimmune diseases
- patients
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
Abstract
Natalizumab est un traitement sûr et efficace des maladies inflammatoires et auto-immunes, comme la sclérose en plaques, la maladie de Crohn et la polyarthrite rhumatoïde. L'échange de chaînes entre le natalizumab et des molécules d'IgG4 agit pour réduire la concentration de natalizumab bivalent présent après l'administration du natalizumab, et réduire ainsi l'activité du natalizumab chez le patient. Des différences des concentrations d'IgG4 parmi les patients ou chez un seul patient avec le temps modifieront le profil pharmacocinétique du natalizumab. Les patients avec des concentrations inférieures d'IgG4 peuvent présenter des concentrations nadir supérieures de natalizumab au cours d'une période posologique. Le suivi des concentrations d'IgG4 et/ou de natalizumab bivalent, et la détermination d'une dose ou d'une période posologique en fonction du suivi peuvent améliorer l'innocuité et/ou l'efficacité d'une thérapie avec natalizumab.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77919006P | 2006-03-03 | 2006-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30287B1 true MA30287B1 (fr) | 2009-03-02 |
Family
ID=38475386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31249A MA30287B1 (fr) | 2006-03-03 | 2008-09-17 | Procedes de traitement de maladies inflammatoires et auto-immunes avec du natalizumab |
Country Status (18)
Country | Link |
---|---|
US (4) | US20070231319A1 (fr) |
EP (2) | EP3360900A1 (fr) |
JP (2) | JP5504390B2 (fr) |
KR (1) | KR20080104343A (fr) |
CN (1) | CN101437541A (fr) |
AU (1) | AU2007224228B2 (fr) |
BR (1) | BRPI0708392A2 (fr) |
CA (1) | CA2644110A1 (fr) |
EA (1) | EA016626B1 (fr) |
ES (1) | ES2663377T3 (fr) |
HK (1) | HK1256238A1 (fr) |
IL (1) | IL193775A (fr) |
MA (1) | MA30287B1 (fr) |
MX (1) | MX2008011176A (fr) |
RS (1) | RS20080391A (fr) |
SG (1) | SG170058A1 (fr) |
WO (1) | WO2007103112A2 (fr) |
ZA (1) | ZA200807346B (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101351710B (zh) | 2005-04-04 | 2013-06-05 | 生物基因Idecma公司 | 评价对治疗性蛋白质的免疫应答的方法和产品 |
CA2641513C (fr) | 2006-02-28 | 2021-09-21 | Elan Pharmaceuticals, Inc. | Methodes pour traiter des maladies inflammatoires et auto-immunes avec du natalizumab |
WO2007100763A2 (fr) | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Méthodes pour traiter des maladies inflammatoires et auto-immunes avec des composés inhibiteurs alpha-4 |
KR20080104343A (ko) | 2006-03-03 | 2008-12-02 | 엘란 파마슈티칼스, 인크. | 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법 |
AU2008234248C1 (en) * | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
EP2200611A4 (fr) * | 2007-09-14 | 2010-09-22 | Biogen Idec Inc | Compositions et procédés de traitement de la leucoencéphalopathie multifocale progressive (lemp) |
EP2226392A1 (fr) * | 2009-03-03 | 2010-09-08 | Assistance Publique - Hôpitaux de Paris | Méthode pour la détection d'infection par le virus JC |
ES2548999T3 (es) * | 2009-06-19 | 2015-10-22 | Teva Pharmaceutical Industries Ltd. | Tratamiento de la esclerosis múltiple con laquinimod |
JP5882208B2 (ja) * | 2009-07-30 | 2016-03-09 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドによるクローン病の治療 |
AU2010282948C1 (en) | 2009-08-10 | 2017-03-02 | Active Biotech, Ab | Treatment of BDNF-related disorders using laquinimod |
EP2485762B1 (fr) * | 2009-10-11 | 2017-12-13 | Biogen MA Inc. | Tests associés à un anti-vla-4 |
AU2011203815B2 (en) | 2010-01-11 | 2015-11-26 | Biogen Ma Inc. | Assay for JC virus antibodies |
US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
MX337614B (es) | 2010-03-03 | 2016-03-10 | Teva Pharma | Tratamiento de lupus nefritis usando laquinimod. |
ES2601819T3 (es) * | 2010-03-03 | 2017-02-16 | Teva Pharmaceutical Industries Ltd. | Tratamiento de la artritis lúpica usando laquinimod |
SG183513A1 (en) * | 2010-03-03 | 2012-09-27 | Teva Pharma | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
MX353144B (es) | 2010-04-20 | 2017-12-20 | Genmab As | Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas. |
LT3326645T (lt) | 2010-10-25 | 2020-08-10 | Biogen Ma Inc. | Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai |
AU2012262322B2 (en) * | 2011-05-30 | 2016-11-03 | Autotelic Llc | Methods and compositions for therapeutic drug monitoring and dosing by point-of-care pharmacokinetic profiling |
EP2766020A4 (fr) | 2011-10-12 | 2015-04-01 | Teva Pharma | Traitement de la sclérose en plaques par combinaison de laquinimod et de fingolimod |
AU2012328322A1 (en) | 2011-10-27 | 2014-06-12 | Genmab A/S | Production of heterodimeric proteins |
SG11201404214QA (en) | 2012-02-03 | 2014-08-28 | Teva Pharma | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
WO2014193804A1 (fr) | 2013-05-28 | 2014-12-04 | Biogen Idec Ma Inc. | Méthodes d'évaluation de risque de développement d'une lemp |
US10865253B2 (en) | 2014-12-19 | 2020-12-15 | Genmab A/S | Rodent bispecific heterodimeric proteins |
CN104865389B (zh) * | 2015-05-28 | 2017-06-06 | 卫生部北京医院 | 一种检测人血清杂合轻链抗体的方法及试剂盒 |
US9856497B2 (en) | 2016-01-11 | 2018-01-02 | The Board Of Trustee Of The Leland Stanford Junior University | Chimeric proteins and methods of regulating gene expression |
MX2018008345A (es) | 2016-01-11 | 2018-12-06 | Univ Leland Stanford Junior | Proteínas quiméricas y métodos de inmunoterapia. |
US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
US11200986B2 (en) * | 2017-11-10 | 2021-12-14 | Reliant Immune Diagnostics, Inc. | Database and machine learning in response to parallel serial dual microfluidic chip |
EP3724660A1 (fr) * | 2017-12-13 | 2020-10-21 | GLX Analytix ApS | Marqueurs biologiques pour la sclérose en plaques |
CN110297093B (zh) * | 2019-03-18 | 2022-04-22 | 山西瑞豪生物科技有限公司 | 一种检测人免疫球蛋白g4的方法和试剂盒 |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4235601A (en) | 1979-01-12 | 1980-11-25 | Thyroid Diagnostics, Inc. | Test device and method for its use |
US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
US4703017C1 (en) | 1984-02-14 | 2001-12-04 | Becton Dickinson Co | Solid phase assay with visual readout |
CA1291031C (fr) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Methode pour la detection de liants specifiques et des substances liables par ceux-ci |
US5763262A (en) | 1986-09-18 | 1998-06-09 | Quidel Corporation | Immunodiagnostic device |
EP1248112A3 (fr) | 1987-04-27 | 2004-08-25 | Inverness Medical Switzerland GmbH | Dispositif d'essai immunochromatographique à liaison spécifique |
US4943522A (en) | 1987-06-01 | 1990-07-24 | Quidel | Lateral flow, non-bibulous membrane assay protocols |
US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
US4818677A (en) | 1987-12-03 | 1989-04-04 | Monoclonal Antibodies, Inc. | Membrane assay using focused sample application |
AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
US5221616A (en) | 1988-07-15 | 1993-06-22 | Quidel Corporation | Prevention of spontaneous complement activation in mammalian biological fluids |
US5118630A (en) | 1988-11-04 | 1992-06-02 | Quidel Corporation | Method for determining periodic infertility in females |
US6352862B1 (en) | 1989-02-17 | 2002-03-05 | Unilever Patent Holdings B.V. | Analytical test device for imuno assays and methods of using same |
US6033665A (en) * | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
US5084828A (en) | 1989-09-29 | 1992-01-28 | Healthtech Services Corp. | Interactive medication delivery system |
US5252496A (en) | 1989-12-18 | 1993-10-12 | Princeton Biomeditech Corporation | Carbon black immunochemical label |
US5096837A (en) | 1990-02-08 | 1992-03-17 | Pacific Biotech, Inc. | Immunochromatographic assay and method of using same |
US5223220A (en) | 1990-03-27 | 1993-06-29 | Pacific Biotech, Inc. | Solid phase immunoassay device and method of making same |
US5118428A (en) | 1990-11-13 | 1992-06-02 | Quidel | Method to remove red blood cells from whole blood samples |
DE4139840B4 (de) | 1990-12-04 | 2005-06-02 | Quidel Corp., San Diego | Antigen-Zubereitung zum Nachweis von H. pylori |
WO1992012428A1 (fr) | 1991-01-11 | 1992-07-23 | Quidel Corporation | Methode de dosage en une seule phase a flux lateral sur support non spongieux |
US5213796A (en) | 1991-05-06 | 1993-05-25 | Dana Farber Cancer Institute | Assay for polyomavirus in humans and uses thereof |
US5225328A (en) | 1991-05-30 | 1993-07-06 | Quidel Corporation | Stable alkaline phosphatase compositions with color enhancement and their use in assays |
US5686315A (en) | 1991-06-14 | 1997-11-11 | Quidel Corporation | Assay device for one step detection of analyte |
EP0646179A4 (fr) | 1992-02-04 | 1996-10-02 | Quidel Corp | Procede d'extraction simplifie d'antigenes bacteriens au moyen de reactifs deshydrates. |
US5541069A (en) | 1992-02-28 | 1996-07-30 | Quidel Corporation | Assay having improved dose response curve |
JP2948318B2 (ja) | 1992-03-10 | 1999-09-13 | クイデル コーポレイション | 特異的結合アッセイ用の赤血球の分離方法 |
DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
US5415994A (en) | 1993-08-02 | 1995-05-16 | Quidel Corporation | Lateral flow medical diagnostic assay device with sample extraction means |
US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US5434057A (en) | 1994-02-02 | 1995-07-18 | Quidel Corporation | Sperm motility assay and devices |
US5521102A (en) | 1994-08-08 | 1996-05-28 | Quidel Corporation | Controlled sensitivity immunochromatographic assay |
US5845255A (en) | 1994-10-28 | 1998-12-01 | Advanced Health Med-E-Systems Corporation | Prescription management system |
US6551593B1 (en) * | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
US5712172A (en) | 1995-05-18 | 1998-01-27 | Wyntek Diagnostics, Inc. | One step immunochromatographic device and method of use |
US5804452A (en) | 1995-04-27 | 1998-09-08 | Quidel Corporation | One step urine creatinine assays |
US5786220A (en) | 1995-04-28 | 1998-07-28 | Quidel Corporation | Assays and devices for distinguishing between normal and abnormal pregnancy |
US6319676B1 (en) | 1995-05-02 | 2001-11-20 | Carter Wallace, Inc. | Diagnostic detection device and method |
US5773234A (en) | 1995-08-07 | 1998-06-30 | Quidel Corporation | Method and device for chlamydia detection |
DE19543553B4 (de) | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
US6305377B1 (en) | 1996-12-12 | 2001-10-23 | Michael T. Portwood | System and method for improving compliance of a medical regimen |
US6229011B1 (en) * | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
US6306642B1 (en) | 1997-11-24 | 2001-10-23 | Quidel Corporation | Enzyme substrate delivery and product registration in one step enzyme immunoassays |
US6623981B2 (en) | 1998-01-27 | 2003-09-23 | Bristol-Myers Squibb Company | Detection of patients at risk for developing integrin antagonist/agonist mediated disease states |
US6014631A (en) | 1998-04-02 | 2000-01-11 | Merck-Medco Managed Care, Llc | Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry |
US6045501A (en) | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
US6407066B1 (en) * | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US7171371B2 (en) | 1999-09-03 | 2007-01-30 | Smg Trust | Method and system for providing pre and post operative support and care |
JP2003511698A (ja) | 1999-10-12 | 2003-03-25 | コンネクス・ゲゼルシャフト・ツーア・オプティミエルング・フォン・フォルシュング・ウント・エントヴィックルング・エムベーハー | 便中の酸耐性微生物の改良された検出方法 |
US6388084B1 (en) * | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
ES2415708T3 (es) * | 1999-12-16 | 2013-07-26 | Biogen Idec Ma Inc. | Métodos de tratamiento de la lesión isquémica o hemorrágica del sistema nervioso central mediante el uso de antagonistas anti-integrina alfa4 |
CA2405448A1 (fr) | 2000-03-30 | 2001-10-11 | Nippon Kayaku Kabushiki Kaisha | Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif |
US6620626B1 (en) | 2000-08-09 | 2003-09-16 | Mission Research Corp. | Antigen detection device and method |
MY129000A (en) * | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
DE60135147D1 (de) | 2000-10-17 | 2008-09-11 | Besst Test Aps | Nen biologischen zelle in einer körperflüssigkeitsprobe |
US6315720B1 (en) | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
US6485460B2 (en) | 2001-01-12 | 2002-11-26 | Bracco Diagnostics, Inc. | Tamper evident syringe barrel |
JP4264348B2 (ja) | 2001-08-20 | 2009-05-13 | プロテオム システムズ リミテッド | 診断検査方法および装置 |
WO2003016902A1 (fr) | 2001-08-20 | 2003-02-27 | Proteome Systems Intellectual Property Pty Ltd | Procede et appareil d'epreuve diagnostique |
US6605602B1 (en) * | 2001-09-28 | 2003-08-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Method of treating BK virus nephropathy |
EP1554576B9 (fr) | 2001-12-03 | 2008-08-20 | Amgen Fremont Inc. | Identification de molecules de haute affinite par depistage par dilutions limitees |
AU2003213231A1 (en) | 2002-02-25 | 2003-09-09 | Elan Pharmaceuticals, Inc. | Administration of agents for the treatment of inflammation |
TWI281470B (en) * | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
TW200307671A (en) * | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
US8478604B2 (en) | 2002-06-21 | 2013-07-02 | Mckesson Technologies Inc. | Closed loop medication use system and method |
US20070275481A1 (en) * | 2003-11-24 | 2007-11-29 | Biogen Idec Ma Inc. | Methods For Detecting Half-Antibodies Using Chip Based Gel Electophoresis |
JP4672263B2 (ja) | 2004-01-27 | 2011-04-20 | デンカ生研株式会社 | 簡便な検出法、検出装置及び検出キットとその製法 |
US7419666B1 (en) | 2004-02-23 | 2008-09-02 | Massachusetts Eye And Ear Infirmary | Treatment of ocular disorders |
TW201705980A (zh) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
US20050283385A1 (en) | 2004-06-21 | 2005-12-22 | The Permanente Medical Group, Inc. | Individualized healthcare management system |
MX2007000228A (es) * | 2004-07-08 | 2007-03-30 | Elan Pharm Inc | Antagonistas de vla-4 multivalentes que comprenden porsiones de polietilenglicol. |
CA2478458A1 (fr) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Traitement de la sclerose en plaques pediatrique |
NZ556105A (en) * | 2004-12-03 | 2009-12-24 | Biogen Idec Inc | Delaying or preventing onset of multiple sclerosis |
WO2006112951A2 (fr) | 2005-03-03 | 2006-10-26 | Seedlings Life Science Ventures, Llc | Methode de gestion des risques concernant les patients soumis a un traitement a base de natalizumab |
CN101351710B (zh) | 2005-04-04 | 2013-06-05 | 生物基因Idecma公司 | 评价对治疗性蛋白质的免疫应答的方法和产品 |
BRPI0616687A2 (pt) | 2005-09-29 | 2011-06-28 | Elan Pharm Inc | compostos de pirimidinil amida que inibem a adesão leucocitária mediada por vla-4 |
CA2643838A1 (fr) * | 2006-02-27 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Composes de sulfonamide de pyrimidinyle inhibant l'adhesion leucocytaire mediee par vla-4 |
CA2641513C (fr) | 2006-02-28 | 2021-09-21 | Elan Pharmaceuticals, Inc. | Methodes pour traiter des maladies inflammatoires et auto-immunes avec du natalizumab |
WO2007100763A2 (fr) | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Méthodes pour traiter des maladies inflammatoires et auto-immunes avec des composés inhibiteurs alpha-4 |
KR20080104343A (ko) | 2006-03-03 | 2008-12-02 | 엘란 파마슈티칼스, 인크. | 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법 |
US20080233150A1 (en) | 2006-11-16 | 2008-09-25 | Gale Smith | Respiratory syncytial virus-virus like particle (vlps) |
EP1933140B1 (fr) | 2006-12-11 | 2011-08-17 | AraGen Biotechnology Co. Ltd. | Procédé pour la détection des anticorps par un signal d'or colloïdal amplifié par des oligonucléotides |
CN102369436B (zh) | 2009-02-05 | 2014-10-22 | 生物基因Idecma公司 | 用于检测jc多瘤病毒的方法 |
WO2010096674A2 (fr) | 2009-02-20 | 2010-08-26 | The Regents Of The University Of California | Dosages de biomarqueur a+ |
AU2011203815B2 (en) | 2010-01-11 | 2015-11-26 | Biogen Ma Inc. | Assay for JC virus antibodies |
HUE061244T2 (hu) | 2011-05-31 | 2023-06-28 | Biogen Ma Inc | A PML kockázat értékelésének módszere |
WO2014193804A1 (fr) | 2013-05-28 | 2014-12-04 | Biogen Idec Ma Inc. | Méthodes d'évaluation de risque de développement d'une lemp |
-
2007
- 2007-03-02 KR KR1020087023464A patent/KR20080104343A/ko not_active Application Discontinuation
- 2007-03-02 ES ES07751993.2T patent/ES2663377T3/es active Active
- 2007-03-02 JP JP2008558307A patent/JP5504390B2/ja active Active
- 2007-03-02 AU AU2007224228A patent/AU2007224228B2/en active Active
- 2007-03-02 SG SG201101499-0A patent/SG170058A1/en unknown
- 2007-03-02 EP EP17206297.8A patent/EP3360900A1/fr active Pending
- 2007-03-02 RS RSP-2008/0391A patent/RS20080391A/sr unknown
- 2007-03-02 WO PCT/US2007/005265 patent/WO2007103112A2/fr active Application Filing
- 2007-03-02 CA CA002644110A patent/CA2644110A1/fr not_active Abandoned
- 2007-03-02 EP EP07751993.2A patent/EP1991267B1/fr not_active Revoked
- 2007-03-02 MX MX2008011176A patent/MX2008011176A/es not_active Application Discontinuation
- 2007-03-02 EA EA200801933A patent/EA016626B1/ru not_active IP Right Cessation
- 2007-03-02 BR BRPI0708392-0A patent/BRPI0708392A2/pt not_active IP Right Cessation
- 2007-03-02 CN CNA2007800158155A patent/CN101437541A/zh active Pending
- 2007-03-02 US US11/713,000 patent/US20070231319A1/en not_active Abandoned
-
2008
- 2008-08-26 ZA ZA200807346A patent/ZA200807346B/xx unknown
- 2008-08-31 IL IL193775A patent/IL193775A/en not_active IP Right Cessation
- 2008-09-17 MA MA31249A patent/MA30287B1/fr unknown
-
2012
- 2012-03-20 US US13/425,058 patent/US10466251B2/en active Active
- 2012-12-03 JP JP2012264135A patent/JP5883377B2/ja active Active
-
2018
- 2018-11-28 HK HK18115236.2A patent/HK1256238A1/zh unknown
-
2019
- 2019-09-30 US US16/588,098 patent/US11333670B2/en active Active
-
2022
- 2022-05-16 US US17/745,409 patent/US20230082238A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10466251B2 (en) | 2019-11-05 |
IL193775A0 (en) | 2011-08-01 |
US20200166521A1 (en) | 2020-05-28 |
EP1991267A2 (fr) | 2008-11-19 |
EP1991267A4 (fr) | 2010-02-10 |
CN101437541A (zh) | 2009-05-20 |
US20070231319A1 (en) | 2007-10-04 |
EA200801933A1 (ru) | 2009-04-28 |
EP3360900A1 (fr) | 2018-08-15 |
RS20080391A (en) | 2009-07-15 |
ZA200807346B (en) | 2009-09-30 |
US11333670B2 (en) | 2022-05-17 |
WO2007103112A2 (fr) | 2007-09-13 |
HK1256238A1 (zh) | 2019-09-20 |
JP5883377B2 (ja) | 2016-03-15 |
JP2013067640A (ja) | 2013-04-18 |
EA016626B1 (ru) | 2012-06-29 |
US20230082238A1 (en) | 2023-03-16 |
WO2007103112A3 (fr) | 2007-11-29 |
JP5504390B2 (ja) | 2014-05-28 |
SG170058A1 (en) | 2011-04-29 |
AU2007224228B2 (en) | 2013-09-19 |
BRPI0708392A2 (pt) | 2011-05-24 |
AU2007224228A1 (en) | 2007-09-13 |
MX2008011176A (es) | 2008-09-10 |
JP2009529043A (ja) | 2009-08-13 |
ES2663377T3 (es) | 2018-04-12 |
EP1991267B1 (fr) | 2017-12-20 |
KR20080104343A (ko) | 2008-12-02 |
IL193775A (en) | 2012-08-30 |
US20120177642A1 (en) | 2012-07-12 |
CA2644110A1 (fr) | 2007-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30287B1 (fr) | Procedes de traitement de maladies inflammatoires et auto-immunes avec du natalizumab | |
Nasermoaddeli et al. | Balneotherapy in medicine: a review | |
WO2004001383A3 (fr) | Formulations de complements alimentaires sures et efficaces et regimes associes destines a prevenir et/ou a traiter des maladies ciblees, des troubles medicaux ou des etats pathologiques, et procedes associes | |
BRPI0410296A (pt) | sistema e método para a determinação da eficácia de tratamento de distúrbios neurológicos utilizando o eletroencefalograma | |
RS20150135A1 (en) | TREATMENT WITH ANTI-VEGF ANTIBODIES | |
WO2007090144A3 (fr) | Système et méthodes de traitement de maladies rétiniennes | |
DE602004030353D1 (de) | Formulierungen enthaltend salicylate und deren verwendung zur behandlung von entzündlicher darmerkrankung | |
ATE470151T1 (de) | Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern | |
WO2006047475A3 (fr) | Detection et analyse de molecules fluorescentes relatives a l'ophtalmologie | |
JP2018502884A5 (fr) | ||
WO2007081486A3 (fr) | Administration orale de defensines pour traiter des maladies intestinales | |
RU2393889C1 (ru) | Способ лечения больных хронической лимфовенозной недостаточностью нижних конечностей | |
ATE495750T1 (de) | Sulfatide zur behandlung von autoimmunkrankheiten | |
MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
RU2038102C1 (ru) | Способ лечения вибрационной болезни | |
Öztop et al. | Complex regional pain syndrome associated with herpes zoster: a case report | |
WO2006091729A3 (fr) | Revascularisation de tissu retinien ischemique et procede de criblage associe | |
RU2445063C1 (ru) | Способ повышения адаптационных возможностей и уровня здоровья работников предприятий с особо опасными и вредными условиями труда | |
RU2104060C1 (ru) | Способ лечения вибрационной болезни | |
DE60131100D1 (de) | Verfahren zur behandlung bestimmter augenkrankheiten | |
RU2157197C1 (ru) | Способ медицинской реабилитации постинсультных больных | |
RU2515406C1 (ru) | Способ восстановительного лечения больных хроническим панкреатитом у работников с вредными условиями труда | |
RU2314084C2 (ru) | Способ лечения вибрационной болезни, ассоциированной с гипертонической болезнью | |
RU2004134391A (ru) | Способ лечения больных синдромом хронической усталости | |
RU2368383C1 (ru) | Продукт диетического питания "прометей", обладающий восстановительным нейрореабилитационным действием у пациентов в отдаленном периоде перенесенных острых цереброваскулярных заболеваний и травматических повреждений центральной нервной системы |